Definitive Contract 75F40121C00132
Award Date
9/22/21
Potential Completion Date
12/28/23
Potential Value
$299K
Federal Agency
Food and Drug Administration
Awardee
The University Of Auckland
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost No Fee
Place of Performance
El Cajon, CA 92019, USA
Solicitation Procedures
Basic Research
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Food and Drug Administration (FDA) awarded a $554,827 firm fixed-price contract to The University of Auckland Research Office Division, a non-profit educational institution based in New Zealand. The contract is for the development of in-vitro tools to simulate the chewing of pharmaceutical opioid drug products. This work will help the FDA evaluate the swallowability and other critical attributes of opioid medications. The contract does not have a set-aside designation, indicating the...
The Food and Drug Administration (FDA) has awarded a $1,000,995 prime contract to the non-profit University of Eastern Finland (Ita-Suomen Yliopisto) to conduct research on "Understanding Preservative Effects on Bioequivalence of Topical Ocular Product." This definitive, firm fixed-price contract is part of the FDA's Broad Agency Announcement for Advanced Research and Development of Regulatory Science and is expected to be completed by November 2026. The contract aligns with the...
The Food and Drug Administration (FDA) awarded a $527,318.00 definitive contract to Uppsala Universitet, a Swedish educational institution, to conduct research and development on model-integrated strategies for bioequivalence evaluation of drugs with high variability and/or long half-life. This contract was awarded under the FDA's Broad Agency Announcement, which seeks proposals to advance regulatory science in various areas. The contract has no set-aside designation and is intended to support...
The U.S. Food and Drug Administration (FDA) awarded a $400,000.00 firm-fixed price contract to the Regents of the University of Michigan, Office of Research and Sponsored Projects (University of Michigan) to advance the science of in vitro, animal model, pharmacokinetic studies, and/or real-world evidence studies to facilitate drug development, including studies focused on antimicrobial resistance and drug development. This contract has a period of performance through March 31, 2026. The...
The U.S. Food and Drug Administration (FDA) awarded a Firm Fixed Price Definitive Contract to the University of Sydney, doing business as the International Clinical Trials Symposium, to "IMPROVE SCIENTIFIC APPROACHES TO EVALUATE GENERIC DRUGS". The contract, valued at $1,234,519.00, has an ultimate completion date of September 29, 2025. The University of Sydney is a leading Australian educational institution that frequently collaborates with U.S. agencies and research organizations...
The U.S. Food and Drug Administration (FDA) awarded a $696,359 firm-fixed-price contract to Duke University's Office of Research Administration Division to conduct research and development activities in support of regulatory science and innovation. The contract, which does not have a set-aside designation, originated from a Broad Agency Announcement (BAA) that solicits advanced proposals across nine key areas to advance scientific knowledge in support of the FDA's mission to protect public...
The Department of Health and Human Services (HHS) Food and Drug Administration (FDA) awarded a $743,717.94 Definitive Contract to the National Institute For Pharmaceutical Technology & Education Inc. (Nipte), a non-profit organization, to conduct research and development on the assessment of smoking and vaping risk of opioids and commercial products, as well as the standardization of methods to assess these properties. This contract was issued under the FDA's Broad Agency Announcement...
This federal contract award was issued by the Food and Drug Administration (FDA), a civilian agency, to The University of Iowa, a large public research university. The contract is for "OTHER MEDICAL (APPLIED/EXPLORATORY)" services and has a ceiling value of $84,541.69. It is a definitive contract with a cost-no-fee pricing type. The contract is designated as an 8(a) sole source set-aside, indicating it was awarded to a small disadvantaged business under the Small Business...
The U.S. Food and Drug Administration (FDA) awarded a $1,530,889.00 definitive, cost-no-fee contract to the University of Connecticut (UConn) to conduct research on "Investigating the Impact of API Purity, Excipient Source and Manufacturing Process on Performance and Quality of Complex siRNA Lipid Nanoparticles". This is a 4-year contract running from September 2023 to September 2027. UConn, a non-profit research university, will be the prime contractor with no set-aside designation....
This $7,369,588 federal contract was awarded by the Food and Drug Administration (FDA) to the Regents of the University of Michigan. The contract is titled "In Vivo Predictive Dissolution (IPD) to Advance Oral Product Bioequivalence (BE) Regulation" and aims to develop improved methods for assessing the bioequivalence of oral drug products. The contract has three main objectives: 1) Mass transport analysis of the gastrointestinal tract, 2) Development and validation of gastrointestinal...